Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine

被引:56
作者
Malayala, Srikrishna, V [1 ]
Mohan, Gisha [2 ]
Vasireddy, Deepa [3 ]
Atluri, Paavani [4 ]
机构
[1] Temple Univ Hosp & Med Sch, Internal Med, Philadelphia, PA 19140 USA
[2] Phys Amer Healthcare Access, Med Res, Philadelphia, PA USA
[3] Pediat Grp Acadiana, Pediat, Lafayette, LA USA
[4] Bay Area Hosp, Internal Med, Coos Bay, OR USA
关键词
covid; 19; drug-induced itp; mrna-based vaccine; drug rash; immune thrombocytopenia purpura;
D O I
10.7759/cureus.14099
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mRNA-1273 vaccine, popularly called the "Moderna vaccine" is being widely administered in the United States for the prevention of COVID-19 infection since December 2020. Mild to moderate intensity side effects like low-grade fever, myalgia, chills and malaise were reported in the trials related to the vaccine. With this case report, we report a case of purpuric rash and thrombocytopenia after receiving the first dose of the m-RNA-1273 vaccine. The patient, in this case, is a 60-year-old male patient who received the first vaccine dose and within two days, he developed diffuse papular rash associated with some thrombocytopenia. He had a history of tobacco use, Hepatitis C liver cirrhosis, chronic kidney disease stage 4, untreated hypertension and systolic congestive heart failure at the baseline. With review of the limited literature related to the vaccine and its side effect profile and with no other etiology explaining the sudden onset of rash, we attribute this thrombocytopenia and purpuric rash as the side effects of the mRNA-1273 vaccine.
引用
收藏
页数:4
相关论文
共 20 条
[1]  
[Anonymous], 2021, COVID ARM SOME DEV D
[2]  
[Anonymous], 2021, COVID-19 Coronavirus Pandemic
[3]  
[Anonymous], 2021, COVID 19 CANDIDATE V
[4]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[5]   MMR vaccine and idiopathic thrombocytopaenic purpura [J].
Black, C ;
Kaye, JA ;
Jick, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (01) :107-111
[6]   Vaccine administration and the development of immune thrombocytopenic purpura in children [J].
Cecinati, Valerio ;
Principi, Nicola ;
Brescia, Letizia ;
Giordano, Paola ;
Esposito, Susanna .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (05) :1158-1162
[7]   The ITP syndrome: pathogenic and clinical diversity [J].
Cines, Douglas B. ;
Bussel, James B. ;
Liebman, Howard A. ;
Prak, Eline T. Luning .
BLOOD, 2009, 113 (26) :6511-6521
[8]   Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children [J].
France, Eric K. ;
Glanz, Jason ;
Xu, Stanley ;
Hambidge, Simon ;
Yamasaki, Kristi ;
Black, Steve B. ;
Marcy, Michael ;
Mullooly, John P. ;
Jackson, Lisa A. ;
Nordin, James ;
Belongia, Edward A. ;
Hohman, K. ;
Chen, Robert T. ;
Davis, Robert .
PEDIATRICS, 2008, 121 (03) :E687-E692
[9]  
GEORGE JN, 1990, BLOOD, V76, P859
[10]   Vaccines, adjuvants and autoimmunity [J].
Guimaraes, Luisa Eca ;
Baker, Britain ;
Perricone, Carlo ;
Shoenfeld, Yehuda .
PHARMACOLOGICAL RESEARCH, 2015, 100 :190-209